36Kr Holdings Inc. to Report Second Half and Fiscal Year 2024 Financial Results on Tuesday, March 11, 2025
BEIJING, March 04, 2025 (GLOBE NEWSWIRE) -- 36Kr Holdings Inc. ('36Kr' or the 'Company') (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced that it will report its second half and fiscal year 2024 unaudited financial results, on Tuesday, March 11, 2025, before the open of U.S. markets.
The Company's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on March 11, 2025 (8:00 p.m. Beijing/Hong Kong Time on March 11, 2025).
For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration and dial in 5 minutes prior to the scheduled call start time. Upon registration, each participant will receive dial-in details to join the conference call.
Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at http://ir.36kr.com.
A replay of the conference call will be available for one week from the date of the conference, by dialing the following telephone numbers:
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services and subscription services to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by comprehensive database and strong data analytics capabilities. Through diverse service offerings and the significant brand influence, the Company is well-positioned to continuously capture the high growth potentials of China's New Economy.
For more information, please visit: http://ir.36kr.com.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
Piacente Financial Communications
Jenny Cai
Tel: +86 (10) 6508-0677
In the United States:
Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Drug maker Indivior joins the flight from London share listings
Drug maker Indivior has become the latest major UK listed company to scrap its London share trading. The pharmaceuticals company, which has its UK headquarters in Slough, said it planned to cancel its secondary listing in London. Indivior only moved its primary listing to Nasdaq last June and now wants to sever all share trading links with the City. The move comes just a year after Invidior's board said it planned to keep the London listing "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Reasons given for scrapping the London listing following a review include the fact that 80% of the company's revenue is generated in America; trading on Nasdaq accounts for approximately 75% of total volumes across both exchanges; more than 70% of the share are now held by investors located in the U.S; and the elimination of 'the cost and complexity of maintaining a secondary listing.' Another major factor is that the company's biggest selling drug Sublocade, a treatment for helping opioid addicts reduce their dependence, has its biggest market in the US. Last year Sublocade accounted for $756 million of the company's total $1.2 billion sales. Indivior was spun out of its former parent company, the consumer products giant Reckitt Benckizer in 2014 as a free standing London listed company. The Virginia based company's chair David Wheadon, said:"We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. 'We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." London has suffered a major outflow of listed companies over recent years in a blow to the prestige of the City. A total of 88 firms delisted or transferred their primary listing from the London Stock Exchange last year, the highest number since the financial crisis of 2008, according to auditor EY. Only 18 companies came on to the London market last year as the vital flow of small and growing businesses raising capital by listing their shares on the London stock market dried up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
an hour ago
- Bloomberg
Tom Cruise's Final ‘Mission Impossible' Tops China Box Office
Mission: Impossible – The Final Reckoning posted the biggest opening for a US film in the country this year, defying trade and geopolitical tensions between Washington and Beijing. Paramount Global 's eighth installment in the action franchise earned $25.2 million across 11,847 locations in China during the opening weekend, the studio said in a statement. The film is likely to become the top-performing US release in the country for 2025, with Warner Bros Entertainment Inc. 's A Minecraft Movie so far holding the lead with about $29 million since its April 4 debut, according to ticketing platform Maoyan.
Yahoo
an hour ago
- Yahoo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
